Elda Favari

List of Publications by Year
in descending order

58 papers	2,550 citations	182225 30 h-index	214428 50 g-index
58 all docs	58 docs citations	58 times ranked	3425 citing authors

#	Article	IF	Citations
1	Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterolâ€lowering treatments?. European Journal of Clinical Investigation, 2022, , e13766.	1.7	6
2	High Density Lipoprotein-Based Therapeutics: Novel Mechanism of Probucol in Foam Cells. Frontiers in Cardiovascular Medicine, 2022, 9, 895031.	1.1	1
3	Probucol treatment is associated with an ABCA1-independent mechanism of cholesterol efflux to lipid poor apolipoproteins from foam cell macrophages. BBA Advances, 2021, 1, 100003.	0.7	2
4	Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients. Journal of Medicinal Food, 2020, 23, 658-666.	0.8	12
5	High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases. Metabolism: Clinical and Experimental, 2020, 104, 154141.	1.5	11
6	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines, 2020, 8, 625.	1.4	21
7	Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a). Journal of Clinical Lipidology, 2020, 14, 487-497.e1.	0.6	17
8	Functional pasta consumption in healthy volunteers modulates ABCG1-mediated cholesterol efflux capacity of HDL. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1768-1776.	1.1	6
9	Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits. Canadian Journal of Cardiology, 2019, 35, 1400-1408.	0.8	11
10	Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects. Journal of Clinical Medicine, 2019, 8, 1225.	1.0	13
11	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. Journal of Clinical Medicine, 2019, 8, 2035.	1.0	10
12	High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis. Journal of Cardiovascular Pharmacology, 2018, 71, 325-331.	0.8	32
13	Toward an international consensusâ€"Integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of Clinical Lipidology, 2017, 11, 858-871.e3.	0.6	105
14	Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017, 256, 1-6.	0.4	98
15	Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction. Journal of Lipid Research, 2017, 58, 2051-2060.	2.0	44
16	Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure. Journal of Atherosclerosis and Thrombosis, 2017, 24, 853-862.	0.9	2
17	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 315-320.	1.2	47
18	An Essential Role for Liver ERÎ± in Coupling Hepatic Metabolism to the Reproductive Cycle. Cell Reports, 2016, 15, 360-371.	2.9	90

#	Article	IF	Citations
19	Lomitapide affects HDL composition and function. Atherosclerosis, 2016, 251, 15-18.	0.4	9
20	A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-I Guastalla). Journal of Clinical Lipidology, 2015, 9, 837-846.	0.6	6
21	Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism. Arthritis and Rheumatology, 2015, 67, 1155-1164.	2.9	94
22	Cholesterol Efflux and Reverse Cholesterol Transport. Handbook of Experimental Pharmacology, 2015, 224, 181-206.	0.9	109
23	Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease. Atherosclerosis, 2015, 242, 443-449.	0.4	18
24	Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions. Handbook of Experimental Pharmacology, 2015, 224, 455-482.	0.9	37
25	The natural compound berberine positively affects macrophage functions involved in atherogenesis. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 195-201.	1.1	34
26	Flow-mediated dilation, carotid wall thickness and HDL function in subjects with hyperalphalipoproteinemia. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 777-783.	1.1	28
27	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 609-615.	0.5	132
28	Hydrocortisone directly promotes cholesterol accumulation in macrophages. Annals of the Rheumatic Diseases, 2014, 73, 1274-1276.	0.5	12
29	FRI0258â€…Improvement of Cell Cholesterol Trafficking-Related Lipoprotein Functions in Rheumatoid Arthritis Patients Treated with Adalimumab. Annals of the Rheumatic Diseases, 2014, 73, 477.1-477.	0.5	0
30	Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. Journal of Clinical Lipidology, 2013, 7, 414-422.	0.6	37
31	Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovascular Research, 2013, 100, 36-43.	1.8	49
32	ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects. Journal of Lipid Research, 2013, 54, 238-243.	2.0	33
33	Functional and morphological vascular changes in subjects with familial combined hypolipidemia: An exploratory analysis. International Journal of Cardiology, 2013, 168, 4375-4378.	0.8	15
34	Rac1 and Cholesterol Metabolism in Macrophage. Journal of Cardiovascular Pharmacology, 2013, 62, 418-424.	0.8	9
35	Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis. Journal of Lipid Research, 2012, 53, 984-989.	2.0	38
36	Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3. Circulation: Cardiovascular Genetics, 2012, 5, 42-50.	5.1	115

#	Article	IF	Citations
37	Cellular Cholesterol Efflux Pathways: Impact on Intracellular Lipid Trafficking and Methodological Considerations. Current Pharmaceutical Biotechnology, 2012, 13, 292-302.	0.9	42
38	Novel mutations of ABCA1 transporter in patients with Tangier disease and familial HDL deficiency. Molecular Genetics and Metabolism, 2012, 107, 534-541.	0.5	28
39	Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism. Atherosclerosis, 2011, 215, 70-76.	0.4	21
40	Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias. Clinical Lipidology, 2010, 5, 329-337.	0.4	7
41	Structure and function of the apoA-IV T347S and Q360H common variants. Biochemical and Biophysical Research Communications, 2010, 393, 126-130.	1.0	12
42	Small Discoidal Pre-Î²1 HDL Particles Are Efficient Acceptors of Cell Cholesterol via ABCA1 and ABCG1. Biochemistry, 2009, 48, 11067-11074.	1.2	120
43	Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis, 2009, 204, 141-146.	0.4	75
44	A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a caucasian kindred. Atherosclerosis, 2009, 205, 506-511.	0.4	33
45	The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. Journal of Lipid Research, 2008, 49, 954-960.	2.0	54
46	A Unique Protease-sensitive High Density Lipoprotein Particle Containing the Apolipoprotein A-IMilano Dimer Effectively Promotes ATP-binding Cassette A1-mediated Cell Cholesterol Efflux. Journal of Biological Chemistry, 2007, 282, 5125-5132.	1.6	68
47	Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis, 2007, 195, 385-391.	0.4	66
48	Relative Contributions of ABCA1 and SR-BI to Cholesterol Efflux to Serum From Fibroblasts and Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 541-547.	1.1	98
49	Pitavastatin Effect on ATP Binding Cassette A1-Mediated Lipid Efflux from Macrophages: Evidence for Liver X Receptor (LXR)-Dependent and LXR-Independent Mechanisms of Activation by cAMP. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 395-401.	1.3	29
50	Impaired ATP-binding cassette transporter A1-mediated sterol efflux from oxidized LDL-loaded macrophages. FEBS Letters, 2005, 579, 6537-6542.	1.3	22
51	Depletion of Pre-Î²-high Density Lipoprotein by Human Chymase Impairs ATP-binding Cassette Transporter A1- but Not Scavenger Receptor Class B Type I-mediated Lipid Efflux to High Density Lipoprotein. Journal of Biological Chemistry, 2004, 279, 9930-9936.	1.6	112
52	Probucol Inhibits ABCA1-Mediated Cellular Lipid Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2345-2350.	1.1	139
53	Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochemical and Biophysical Research Communications, 2004, 321, 670-674.	1.0	31
54	Cellular cholesterol flux studies: methodological considerations. Atherosclerosis, 2002, 163, 1-8.	0.4	84

#	Article	IF	Citations
55	The C-terminal domain of apolipoprotein A-I is involved in ABCA1-driven phospholipid and cholesterol efflux. Biochemical and Biophysical Research Communications, 2002, 299, 801-805.	1.0	30
56	Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. Journal of Lipid Research, 2001, 42, 1969-1978.	2.0	99
57	Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. Journal of Lipid Research, 2001, 42, 1969-78.	2.0	76
58	CELLULAR TOXICITY OF N -SUBSTITUTED 2,2â€²-DICARBOXAMIDODIPHENYLDISULPHIDES WITH HIGH ANTIMICROBIAL ACTIVITY. Pharmacological Research, 1999, 40, 429-434.	3.1	1